secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001104659-25-055248
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio appoints Jeffrey Blizard as President; Blizard resigns from Board
--------------------------------------------------------------------------

- Blizard resigned from Board effective June 2, 2025; no disagreement with company.
- Blizard appointed President effective same date; Antony Koblish remains CEO, drops President title.
- Annual base salary $475,000; target bonus 50% of salary; cash sign-on $150,000.
- Equity grant: 154,100 stock options (4-yr vest) and 104,800 RSUs (4-yr annual vest).
- Blizard previously Global Head of Surgical Sales at Abiomed (J&J); joined TELA Bio board June 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465925055248/0001104659-25-055248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465925055248/tm2516546d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-055248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer